133 related articles for article (PubMed ID: 3772477)
1. Prediction of tumor doubling time in recurrent meningiomas. Cell kinetics studies with bromodeoxyuridine labeling.
Cho KG; Hoshino T; Nagashima T; Murovic JA; Wilson CB
J Neurosurg; 1986 Dec; 65(6):790-4. PubMed ID: 3772477
[TBL] [Abstract][Full Text] [Related]
2. Meningiomas: clinical implications of a high proliferative potential determined by bromodeoxyuridine labeling.
Shibuya M; Hoshino T; Ito S; Wacker MR; Prados MD; Davis RL; Wilson CB
Neurosurgery; 1992 Apr; 30(4):494-7; discussion 497-8. PubMed ID: 1584346
[TBL] [Abstract][Full Text] [Related]
3. Proliferative potential of recurrent intracranial meningiomas as evaluated by labelling indices of BUdR and Ki-67, and tumour doubling time.
Kakinuma K; Tanaka R; Onda K; Takahashi H
Acta Neurochir (Wien); 1998; 140(1):26-31; discussion 31-2. PubMed ID: 9522904
[TBL] [Abstract][Full Text] [Related]
4. Proliferative potential of human meningiomas of the brain. A cell kinetics study with bromodeoxyuridine.
Hoshino T; Nagashima T; Murovic JA; Wilson CB; Davis RL
Cancer; 1986 Oct; 58(7):1466-72. PubMed ID: 2427189
[TBL] [Abstract][Full Text] [Related]
5. [Proliferation kinetics of human brain tumors by in situ double labeling with bromodeoxyuridine and iododeoxyuridine].
Maeda T; Hoshino T
No To Shinkei; 1992 Sep; 44(9):821-5. PubMed ID: 1476811
[TBL] [Abstract][Full Text] [Related]
6. Correlation of in vitro bromodeoxyuridine labeling index and DNA aneuploidy with survival or recurrence in brain-tumor patients.
Nishizaki T; Orita T; Kajiwara K; Ikeda N; Ohshita N; Nakayama H; Furutani Y; Ikeyama Y; Akimura T; Kamiryo T
J Neurosurg; 1990 Sep; 73(3):396-400. PubMed ID: 1696625
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implications of the bromodeoxyuridine labeling index of human gliomas.
Hoshino T; Prados M; Wilson CB; Cho KG; Lee KS; Davis RL
J Neurosurg; 1989 Sep; 71(3):335-41. PubMed ID: 2549222
[TBL] [Abstract][Full Text] [Related]
8. Bromodeoxyuridine labeling study of intracranial meningiomas: proliferative potential and recurrence.
Lee KS; Hoshino T; Rodriguez LA; Bederson J; Davis RL; Wilson CB
Acta Neuropathol; 1990; 80(3):311-7. PubMed ID: 2399811
[TBL] [Abstract][Full Text] [Related]
9. Flow-cytometric DNA analysis and immunohistochemical measurement of Ki-67 and BUdR labeling indices in human brain tumors.
Nishizaki T; Orita T; Furutani Y; Ikeyama Y; Aoki H; Sasaki K
J Neurosurg; 1989 Mar; 70(3):379-84. PubMed ID: 2536805
[TBL] [Abstract][Full Text] [Related]
10. Prognostic implications of the proliferative potential of low-grade astrocytomas.
Hoshino T; Rodriguez LA; Cho KG; Lee KS; Wilson CB; Edwards MS; Levin VA; Davis RL
J Neurosurg; 1988 Dec; 69(6):839-42. PubMed ID: 3193189
[TBL] [Abstract][Full Text] [Related]
11. Comparison of bromodeoxyuridine labeling indices obtained from tissue sections and flow cytometry of brain tumors.
Nagashima T; Hoshino T; Cho KG; Senegor M; Waldman F; Nomura K
J Neurosurg; 1988 Mar; 68(3):388-92. PubMed ID: 3278075
[TBL] [Abstract][Full Text] [Related]
12. Intracranial meningeal tumours in childhood: a clinicopathologic study including MIB-1 immunohistochemistry.
Demirtaş E; Erşahin Y; Yilmaz F; Mutluer S; Veral A
Pathol Res Pract; 2000; 196(3):151-8. PubMed ID: 10729919
[TBL] [Abstract][Full Text] [Related]
13. Comparison of MIB-1 (Ki-67) antigen and bromodeoxyuridine proliferation indices in meningiomas.
Langford LA; Cooksley CS; DeMonte F
Hum Pathol; 1996 Apr; 27(4):350-4. PubMed ID: 8617477
[TBL] [Abstract][Full Text] [Related]
14. In situ cell kinetics studies on human neuroectodermal tumors with bromodeoxyuridine labeling.
Hoshino T; Nagashima T; Murovic JA; Wilson CB; Edwards MS; Gutin PH; Davis RL; DeArmond SJ
J Neurosurg; 1986 Mar; 64(3):453-9. PubMed ID: 3950723
[TBL] [Abstract][Full Text] [Related]
15. Estimation of growth fraction with bromodeoxyuridine in human central nervous system tumors.
Yoshii Y; Maki Y; Tsuboi K; Tomono Y; Nakagawa K; Hoshino T
J Neurosurg; 1986 Nov; 65(5):659-63. PubMed ID: 3772454
[TBL] [Abstract][Full Text] [Related]
16. Cell kinetics of human brain tumors: in vivo study with bromodeoxyuridine and flow cytometry.
Danova M; Riccardi A; Gaetani P; Wilson GD; Mazzini G; Brugnatelli S; Buttini R; Butti G; Ucci G; Paoletti P
Eur J Cancer Clin Oncol; 1988 May; 24(5):873-80. PubMed ID: 3169092
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of bromodeoxyuridine labeling in primary and recurrent glioblastoma multiforme.
Ritter AM; Sawaya R; Hess KR; Levin VA; Bruner JM
Neurosurgery; 1994 Aug; 35(2):192-8; discussion 198. PubMed ID: 7969825
[TBL] [Abstract][Full Text] [Related]
18. Correlation of histopathological features and proliferative potential of gliomas.
Germano IM; Ito M; Cho KG; Hoshino T; Davis RL; Wilson CB
J Neurosurg; 1989 May; 70(5):701-6. PubMed ID: 2709110
[TBL] [Abstract][Full Text] [Related]
19. Postoperative residual tumor growth of meningioma can be predicted by MIB-1 immunohistochemistry.
Nakaguchi H; Fujimaki T; Matsuno A; Matsuura R; Asai A; Suzuki I; Sasaki T; Kirino T
Cancer; 1999 May; 85(10):2249-54. PubMed ID: 10326705
[TBL] [Abstract][Full Text] [Related]
20. Predicting the recurrence of ependymomas from the bromodeoxyuridine labeling index.
Asai A; Hoshino T; Edwards MS; Davis RL
Childs Nerv Syst; 1992 Aug; 8(5):273-8. PubMed ID: 1394266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
